(Invited) A Three-Biomarker Strategy for Diagnosis of Acute Myocardial Infarction Via a Multiplex Electrochemiluminescence Immunoarray

Abstract

Acute myocardial infarction (AMI) is a cardiovascular diseases characterized by myocardial necrosis resulting from acute and persistent obstruction of a coronary artery. AMI accounts for one third of overall cardiovascular diseases deaths, exceeding the mortality of any single tumor, and shows an increasing trend year by year1-2. Cardiac troponin T is the gold standard for diagnosis of AMI but has insufficient specificity at early times3-4. Herein, we report a three-biomarker strategy (cardiac troponin I, heart type fatty acid binding protein, and copeptin) for rapid, accurate and early diagnosis of AMI via a multiplex electrochemiluminescence immunoarray coupled with robust machine learning. In a >200 subject pilot trial, the three-biomarker joint model achieved 100% sensitivity and specificity across a broad patient population with chest pain, including those patients within three hours of symptom onset. This study is very important for the diagnosis, medical treatment and prognoses of AMI, which holds the potential to minimize AMI mortality as well as to lower medical expenditure.